Swedish Orphan Biovitrum AB (SWOBY)

Overview

Swedish Orphan Biovitrum AB (publ), also known as Sobi, is a globally recognized integrated biotechnology company that has dedicated itself to researching, developing, manufacturing, and marketing pharmaceuticals. The company's focus lies within the therapeutic areas of haematology, immunology, and specialty care, covering a broad range of geographies including Europe, North America, the Middle East, Asia, and Australia. Founded in 1939 and with headquarters in Solna, Sweden, Sobi has established itself as a pivotal player in providing innovative treatments for rare diseases by forging strategic collaborations, such as with Apellis Pharmaceuticals Inc., to enhance its product offerings and expand its global reach.

Products and Services

Swedish Orphan Biovitrum offers an extensive portfolio of pharmaceuticals catering to various rare diseases and conditions:

• Alprolix: A treatment option for haemophilia B, offering patients a chance to manage this rare genetic bleeding disorder effectively.
• Aspaveli®/Empaveli: Designed for adult patients suffering from paroxysmal nocturnal haemoglobinuria, this product offers hope in treating this rare and life-threatening blood disease.
• Doptelet: A therapeutic solution for thrombocytopenia, aiming to address the decreased platelet counts associated with this condition.
• Elocta: Serving patients with haemophilia A, Elocta is focused on improving the care and treatment outcomes for those affected by this genetic disorder.
• Gamifant: Specifically tailored for hemophagocytic lymphohistiocytosis (HLH), Gamifant addresses the needs of patients battling this severe immune system disfunction.
• Zynlonta: A treatment for aggressive malignant diseases, underscoring Sobi's commitment to oncology and complex care needs.
• Kineret: Offering relief for individuals with cryopyrin associated periodic syndrome, rheumatoid arthritis, and Still's disease, showcasing the diversity in Sobi's product lineup.
• Orfadin: A vital treatment option for hereditary tyrosinaemia type-1, aiding in managing this rare metabolic disease.
• Synagis: Tailored for serious lower respiratory tract infection, providing critical care to the most vulnerable patient populations.

In addition to these core products, Sobi also brings to market other significant treatments such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra, expanding its reach within the healthcare sector. Moreover, the company contributes to drug substance development for notable treatments like ReFacto AF/Xyntha for Pfizer, BIVV001 for haemophilia A, and Nirsevimab for respiratory syncytial virus, further showcasing its depth in pharmaceutical development and commitment to enhancing patient care across the globe.